SI9111867B - New pharmaceutical formulations containing active ionizable substance as well as procedure for their preparation - Google Patents

New pharmaceutical formulations containing active ionizable substance as well as procedure for their preparation Download PDF

Info

Publication number
SI9111867B
SI9111867B SI9111867A SI9111867A SI9111867B SI 9111867 B SI9111867 B SI 9111867B SI 9111867 A SI9111867 A SI 9111867A SI 9111867 A SI9111867 A SI 9111867A SI 9111867 B SI9111867 B SI 9111867B
Authority
SI
Slovenia
Prior art keywords
weight
ionizable
complex
ionic complex
active substance
Prior art date
Application number
SI9111867A
Other languages
Slovenian (sl)
Other versions
SI9111867A (en
Inventor
Bengt Magnus Lindstedt
Per Johan Gunnar Lundberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9003903A external-priority patent/SE9003903D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of SI9111867A publication Critical patent/SI9111867A/en
Publication of SI9111867B publication Critical patent/SI9111867B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A preparation of a pharmaceutically active ionizable substance where the active substance is ionically complexed with an ion exchange resin which is worked into a hydrophilically eroding matrix, as well as a procedure for its preparation.

Claims (8)

1 Patentni zahtevki 1. Farmacevtski pripravek za podaljšano sproščanje farmacevtsko aktivne ionizabilne snovi, označen s tem, da obsega ionski kompleks aktivne ionske snovi z nasprotno nabito ionsko izmenjevalno smolo; pri čemer je ionski kompleks vdelan v hidrofdno erodirajočo matrico, ki obstoji iz 100 mas.% do 10 mas.% derivatizirane celuloze in 0 mas.% do 90 mas.% sintetičnega polimera; pri čemer je hidrofilna erodirajoča matrica v takem razmerju glede na kompleks, da povzroči linearno sproščanje aktivne snovi.A pharmaceutical preparation for the prolonged release of a pharmaceutically active ionizable substance, characterized in that it comprises an ionic complex of the active ionic substance with an opposite charged ion exchange resin; wherein the ionic complex is embedded in a hydrophobic eroding matrix consisting of from 100% to 10% by weight of derivatized cellulose and 0% to 90% by weight of a synthetic polymer; wherein the hydrophilic erosion matrix is in such a ratio with respect to the complex to cause a linear release of the active substance. 2. Postopek za pripravo farmacevtskega pripravka po zahtevku 1, označen s tem, da obsega stopnje: (a) kompleksiranja aktivne snovi z nasprotno nabito ionsko izmenjevalno smolo v vodi ali etanolu, da se tvori ionski kompleks; (b) vdelave dobljenega suhega kompleksa v hidrofdno erodirajočo matrico, ki obstoji iz 100 mas.% do 10 mas.% derivatizirane celuloze in 0 mas.% do 90 mas.% sintetičnega polimera, da se tvori suha zmes, ki ima približno razmerje ionskega kompleksa proti hidrofdni matrici 1 : 3; in (c) oblikovanja dobljene zmesi v obliko tablet.A process for the preparation of a pharmaceutical preparation according to claim 1, characterized in that it comprises the steps of: (a) complexing the active substance with a counter charged ion exchange resin in water or ethanol to form an ionic complex; (b) incorporating the resulting dry complex into a hydrophobic eroding matrix consisting of from 100% to 10% by weight of derivatized cellulose and from 0% to 90% by weight of a synthetic polymer to form a dry mixture having a ratio of ionic complex against hydrophobic matrix 1: 3; and (c) forming the resulting mixture into tablet form. 3. Farmacevtski pripravek za podaljšano sproščanje aktivne sestavine, označen s tem, da obsega: (a) ionizabilno aktivno sestavino; (b) ionsko izmenjevalno smolo, ki tvori ionski kompleks z aktivno sestavino; in (c) hidrofdno erodirajočo matrico, ki obstoji iz 100 mas.% do 10 mas.% derivatizirane celuloze in 0% do 90 mas.% sintetičnega polimera, kjer je ionski kompleks vdelan pri primernem masnem razmerju okoli 1 dela ionskega kompleksa proti 3 delom hidrofdne matrice. 2A pharmaceutical preparation for the prolonged release of the active ingredient, characterized in that it comprises: (a) an ionizable active ingredient; (b) an ion exchange resin forming an ionic complex with an active ingredient; and (c) a hydrophobic eroding matrix consisting of from 100% to 10% by weight of derivatized cellulose and from 0% to 90% by weight of a synthetic polymer, wherein the ionic complex is embedded in an appropriate weight ratio of about 1 part of the ion complex to 3 parts hydrophobic matrix. 2 4. Izboljšan oralni farmacevtski pripravek, učinkovit za podaljšano sproščanje farmakološko aktivne snovi iz pripravka, ki vsebuje ionizabilno aktivno snov, ionsko kompleksirano z ionsko izmenjevalno smolo v vodi, pri čemer je ionski kompleks vdelan po sušenju v hidrofilno erodirajočo matrico, ki obstoji iz 100 mas.% do 10 mas.% derivatizirane celuloze in 0 mas.% do 90 mas.% sintetičnega polimera, tako da povzroči hitrost sproščanja aktivne sestavine proti linearnosti, označen s tem, da izboljšanje pripravka obsega masno razmerje okoli 1 : 3 ionskega kompleksa proti hidrofilni erodirajoči matrici.An improved oral pharmaceutical preparation, effective for prolonged release of a pharmacologically active substance from a composition comprising an ionizable active substance ionically complexed with an ion exchange resin in water, the ionic complex being incorporated after drying into a hydrophilic eroding matrix consisting of 100 weight % to 10% by weight of derivatised cellulose and 0% to 90% by weight of a synthetic polymer, to cause the release rate of the active ingredient to linearity, characterized in that the improvement of the composition comprises a mass ratio of about 1: 3 of the ion complex to the hydrophilic eroding matrices. 5. Oralni farmacevtski pripravek za podaljšano sproščanje vodotopne aktivne sestavine, označen s tem, da obsega: (a) ionizabilno vodotopno aktivno sestavino; (b) ionsko izmenjevalno smolo, ki tvori ionski kompleks z aktivno sestavino v vodi; in (c) suho hidrofilno erodirajočo matrico, ki obstoji iz 100 mas.% do 10 mas.% derivatizirane celuloze in 0 mas.% do 90 mas.% sintetičnega polimera; pri čemer je ionski kompleks vdelan po sušenju v hidrofilno matrico pri masnem razmerju okoli 1 : 3 in kjer je podaljšano sproščanje približno linearno.An oral pharmaceutical preparation for the prolonged release of a water soluble active ingredient, characterized in that it comprises: (a) an ionizable water soluble active ingredient; (b) an ion exchange resin forming an ionic complex with an active ingredient in water; and (c) a dry hydrophilic eroding matrix consisting of from 100% to 10% by weight of derivatized cellulose and 0% to 90% by weight of a synthetic polymer; wherein the ionic complex is embedded after drying into a hydrophilic matrix at a ratio of about 1: 3 and wherein the prolonged release is approximately linear. 6. Farmacevtski pripravek za enakomerno podaljšano sproščanje farmakološko aktivne ionizabilne snovi, označen s tem, da obsega ionski kompleks aktivne ionske snovi z nasprotno nabito ionsko izmenjevalno smolo; pri čemer je ionski kompleks vdelan v hidrofilno erodirajočo matrico, ki obstoji iz hidroksipropilmetilceluloze, ki vsebuje 27-30% metoksi skupin in 7-12% hidroksipropoksi skupin; pri čemer je hidrofilna erodirajoča matrica v takem razmerju z ionskim kompleksom, da povzroči enakomerno podaljšano sproščanje aktivne snovi.Pharmaceutical preparation for uniformly prolonged release of a pharmacologically active ionizable substance, characterized in that it comprises an ionic complex of an active ionic substance with an opposite charged ion exchange resin; wherein the ionic complex is embedded in a hydrophilic eroding matrix consisting of hydroxypropylmethylcellulose containing 27-30% of methoxy groups and 7-12% of hydroxypropoxy groups; wherein the hydrophilic eroding matrix is in such a ratio with the ion complex to produce a uniformly prolonged release of the active substance. 7. Oralni farmacevtski pripravek za enakomerno podaljšano sproščanje ionazibilne aktivne snovi, označen s tem, da obsega ionizabilno kislo aktivno snov z vodotopnostjo nad 10 mg/ml; ionizabilno kislo aktivno snov; 3 ionsko izmenjevalno smolo, ki obstoji iz premreženega polimera, ionsko kompleksiranega s kislo aktivno snovjo, da se tvori ionski kompleks, ki je vdelan v hidrofilno erodirajočo matrico, ki obstoji iz derivatizirane celuloze.An oral pharmaceutical preparation for a uniformly prolonged release of an ionizable active substance, characterized in that it comprises an ionizable acidic active substance with a solubility greater than 10 mg / ml; ionizable acidic active substance; 3 ion exchange resin consisting of a crosslinked polymer ionically complexed with an acidic active substance to form an ionic complex embedded in a hydrophilic eroding matrix consisting of derivatized cellulose. 8. Oralni farmacevtski pripravek za enakomerno podaljšano sproščanje ionizabilne aktivne snovi, označen s tem, da obsega ionizabilno bazično aktivno snov z vodotopnostjo nad 10 mg/ml, izbrano iz skupine, ki obstoji iz metoprolola in terbutalina; kationsko izmenjevalno smolo, kije premreženi polimer in kije ionsko kompleksirana z bazično aktivno snovjo, da se tvori ionski kompleks; pri čemer je ionski kompleks vdelan v hidrofilno erodirajočo matrico, ki obstoji iz derivatizirane celuloze.An oral pharmaceutical preparation for uniformly prolonged release of an ionizable active substance, characterized in that it comprises an ionizable basic active substance with a solubility greater than 10 mg / ml selected from the group consisting of metoprolol and terbutaline; a cation exchange resin which is a crosslinked polymer and which is ionically complexed with a basic active substance to form an ionic complex; wherein the ionic complex is embedded in a hydrophilic eroding matrix consisting of derivatized cellulose.
SI9111867A 1990-12-07 1991-11-27 New pharmaceutical formulations containing active ionizable substance as well as procedure for their preparation SI9111867B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003903A SE9003903D0 (en) 1990-12-07 1990-12-07 NEW PHARMACEUTICAL FORMULATIONS
YU186791A YU186791A (en) 1990-12-07 1991-11-27 NEW PHARMACEUTICAL FORMULATIONS CONTAINING A PHARMACEUTICALLY ACTIVE IONIZING SUBSTANCE, AS WELL AS A PROCEDURE FOR OBTAINING THEM

Publications (2)

Publication Number Publication Date
SI9111867A SI9111867A (en) 1998-08-31
SI9111867B true SI9111867B (en) 2001-04-30

Family

ID=26660931

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9111867A SI9111867B (en) 1990-12-07 1991-11-27 New pharmaceutical formulations containing active ionizable substance as well as procedure for their preparation

Country Status (1)

Country Link
SI (1) SI9111867B (en)

Also Published As

Publication number Publication date
SI9111867A (en) 1998-08-31

Similar Documents

Publication Publication Date Title
FI56623C (en) SAETT ATT FRAMSTAELLA ORALT INTAGBARA MEDICINFORMER MED FOERLAENGD VERKAN
US3773920A (en) Sustained release medicinal composition
FI85649B (en) FOERFARANDE FOER FRAMSTAELLNING AV FOER ORAL ANVAENDNING AVSEDDA FASTA LAEKEMEDELSFORMER, SOM INNEHAOLLER 9-DEOXO-11- DEOXI-9,11- / IMINO / 2- (2-METOXIETOXI) ETYLIDEN / OXI / (9S) -ERYTROM
DE69613840T2 (en) ORAL DOSAGE FORM AND METHOD FOR TREATING PAIN CONDITIONS IN THE ORAL CAVE
ES424533A1 (en) Slow release pharmaceutical compositions
AT391078B (en) METHOD FOR THE PRODUCTION OF GRANULES OR OF PRESS TABLETS WITH REGULATED DELIVERY OF ACTIVE SUBSTANCES
EP0250374B1 (en) Therapeutic system for controlled release of drugs
DE1949894B2 (en) SOLID OR GEL-SHAPED MEDICINAL FORM WITH DELAYED SUBSTANCE RELEASE
CA2097176A1 (en) New pharmaceutical formulations containing a pharmacologically active ionizable substance as well as process for the preparation thereof
EA014249B1 (en) Formulation of extended release levetiracetam
PT90466A (en) PREPARATION PROCESS OF PHARMACEUTICAL COMPOSITIONS COMPOSING AN EXTRAGRANULAR EXCIPIENT, INSOLUBLE HYGROSCOPE IN WATER AND AN ACTIVE INGREDIENT, IN PARTICULAR CIMETIDINE
JP2003512317A5 (en)
EP0211991B1 (en) Substained release tablets and method for preparation thereof
DE1467781A1 (en) Process for the production of coated tablets with extended release of active ingredients
KR0177493B1 (en) Process for the preparation of a tablet containing a heat light and moisture sensitive active ingredient having monoclinic crystal structure
EP0921793B1 (en) Solid, non-deliquescent formulations of sodium valproate
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
DE3809764A1 (en) MIXTURE OF ALGINATES AND POLYACRYLATES AND THEIR USE
SI9111867B (en) New pharmaceutical formulations containing active ionizable substance as well as procedure for their preparation
US5230901A (en) Sustained release tablet of a mixture of alginates and polyacrylates
DE2634004A1 (en) Orally administered medicament dissolution acceleration - by using crosslinked insoluble polymers as carrier materials
CH642259A5 (en) GALENIC PREPARATIONS FOR ORAL APPLICATION OF ERGOTAL CALOIDS.
EP0557064B1 (en) Modified release formulation
EP0559702B1 (en) Retarded-action urapidil formulation
KR900011455A (en) Sustained release formulations of the active agent and preparation method thereof